Perspective Therapeutics Inc. Insider Trading

CATX

⊜ Compare

Last 12 months

Insiders bought 42K on the open market and sold nothing.

Net open-market

+42K

2 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

2 / 0

executives and directors

Last open-market buy

Nov 2025

Nov 13, 2025

Get an email when CATX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 3 – 4	Lantheus Alpha Therapy, LLC Large holder	SoldNo plan 2 parts	247,932	$3.14 average	778K	2.2%	Form 4
Sep 2	Lantheus Holdings, Inc. Large holder	SoldNo plan	42,129	$3.11	131K	0.4%	Form 4
Aug 31 – Sep 1	Lantheus Alpha Therapy, LLC Large holder	SoldNo plan 2 parts	113,914	$3.13 average	357K	1.0%	Form 4
Sep 1	Lantheus Holdings, Inc. Large holder	SoldNo plan	35,769	$3.12	112K	0.3%	Form 4
Aug 31	Lantheus Holdings, Inc. Large holder	SoldNo plan	78,145	$3.14	245K	0.7%	Form 4
Nov 13, 2025	Jonathan Robert Hunt Chief Accounting Officer	Bought	11,000	$2.03	22K	23%	Form 4
Nov 12, 2025	Robert F Williamson III Director	Bought	9,498	$2.10	20K	8.7%	Form 4
Mar 28, 2025 – Mar 31, 2025	Robert F Williamson III Director	Bought 2 parts	60,337	$2.19 average	132K	123%	Form 4
Mar 31, 2025	Lori A Woods Director	Bought	23,475	$2.13	50K	14%	Form 4
Mar 28, 2025	Johan M. Spoor Chief Executive Officer	Bought 2 parts	26,676	$2.23 average	60K	44%	Form 4
Mar 28, 2025	Juan Graham Chief Financial Officer	Bought	33,333	$2.25	75K	1649%	Form 4
Dec 4, 2024	Heidi Henson Director	Bought	25,975	$3.85	100K	New	Form 4
Dec 4, 2024	Johan M. Spoor CEO	Bought	8,000	$3.77	30K	17%	Form 4
Nov 25, 2024	Robert F Williamson III Director	Bought 2 parts	6,266	$3.64 average	23K	1.5%	Form 4
Nov 25, 2024	Jonathan Robert Hunt Chief Financial Officer	Bought 4 parts	12,829	$3.82 average	49K	36%	Form 4
Nov 25, 2024	Johan M. Spoor CEO	Bought 3 parts	26,500	$3.79 average	100K	13%	Form 4

Sep 3 – 4No plan
Lantheus Alpha Therapy, LLC
Large holder · sold 247,932 at avg $3.14
778K
2.2% of stake
Sep 2No plan
Lantheus Holdings, Inc.
Large holder · sold 42,129 at $3.11
131K
0.4% of stake
Aug 31 – Sep 1No plan
Lantheus Alpha Therapy, LLC
Large holder · sold 113,914 at avg $3.13
357K
1.0% of stake
Sep 1No plan
Lantheus Holdings, Inc.
Large holder · sold 35,769 at $3.12
112K
0.3% of stake
Aug 31No plan
Lantheus Holdings, Inc.
Large holder · sold 78,145 at $3.14
245K
0.7% of stake
Nov 13, 2025
Jonathan Robert Hunt
Chief Accounting Officer · bought 11,000 at $2.03
22K
23% of stake
Nov 12, 2025
Robert F Williamson III
Director · bought 9,498 at $2.10
20K
8.7% of stake
Mar 28, 2025 – Mar 31, 2025
Robert F Williamson III
Director · bought 60,337 at avg $2.19
132K
123% of stake
Mar 31, 2025
Lori A Woods
Director · bought 23,475 at $2.13
50K
14% of stake
Mar 28, 2025
Johan M. Spoor
Chief Executive Officer · bought 26,676 at avg $2.23
60K
44% of stake
Mar 28, 2025
Juan Graham
Chief Financial Officer · bought 33,333 at $2.25
75K
1649% of stake
Dec 4, 2024
Heidi Henson
Director · bought 25,975 at $3.85
100K
New position
Dec 4, 2024
Johan M. Spoor
CEO · bought 8,000 at $3.77
30K
17% of stake
Nov 25, 2024
Robert F Williamson III
Director · bought 6,266 at avg $3.64
23K
1.5% of stake
Nov 25, 2024
Jonathan Robert Hunt
Chief Financial Officer · bought 12,829 at avg $3.82
49K
36% of stake
Nov 25, 2024
Johan M. Spoor
CEO · bought 26,500 at avg $3.79
100K
13% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CATX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CATX

CompareIntrinsic value

BSPKBespoke Extracts Inc.

$0.00+0.00%30

ATXIAvenue Therapeutics Inc.

$0.40+0.00%10

HYPDHyperion DeFi, Inc.

$3.23+5.74%25

RNACCartesian Therapeutics Inc.

$6.84+6.71%10

DAREDare Bioscience Inc.

$0.66+1.83%10

LPCNLipocine Inc.

$1.44-1.37%40

OVIDOvid Therapeutics Inc.

$2.74+14.17%25

LGVNLongeveron Inc.

$1.78+0.00%10

Held by ETFs

CATX is in 6 US ETFs. The largest of them, with CATX's weight in each:

Spot a number that looks wrong? Check it in CATX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CATX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.